Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Esophageal Squamous Cell Carcinoma 5Neoplasm Metastasis 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Recurrence 3Colorectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1Sarcoma 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Locally Advanced or Metastatic Urothelial Bladder Cancer 1

Interventions

Gemcitabine 5Paclitaxel 4Nivolumab 3cobimetinib 2atezolizumab 2adavosertib 2Ramucirumab 2N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 2Carboplatin 2zansecimab 1tocilizumab 1tivozanib 1tislelizumab 1temsirolimus 1ridaforolimus 1plocabulin 1pexidartinib 1pevonedistat 1pembrolizumab 1pamiparib 1obinutuzumab 1necitumumab 1liposomal doxorubicin 1lenvatinib 1glasdegib 1futuximab 1demplatin pegraglumer 1birinapant 1avelumab 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Tumors × tislelizumab × Clear all
NCT02660034 2021-12-06

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

BeiGene

Phase 1 Completed
229 enrolled 46 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡